What did @thechocolatefamily actually say?
The transcript captured in this video is largely incoherent, consisting of what appears to be song lyrics or ambient audio rather than a coherent spoken claim. The caption, however, tells a different story. The creator states she gained significant weight after having her daughter Naomi, developed a pre-diabetic status alongside body aches and fatigue, and credits Zepbound with reversing that pre-diabetic diagnosis. That is the claim worth examining.
To be direct: we are fact-checking the caption's claims here because the transcript does not contain usable spoken content. The caption says, "I am proud to say I am no longer pre-diabetic" after using Zepbound. That is a meaningful medical claim, and it deserves serious scrutiny rather than a pass because the audio did not cooperate.
Does the science back this up?
Yes, actually, and pretty compellingly. Tirzepatide, the active ingredient in Zepbound, has shown real clinical results in people with pre-diabetes and obesity. This is not just plausible, it is documented.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that tirzepatide produced weight loss of up to 22.5% of body weight in adults with obesity. A follow-up analysis from SURMOUNT-1 published in 2024 found that among participants with pre-diabetes at baseline, 93% achieved normoglycemia after 72 weeks on the highest dose of tirzepatide. That number is striking. For context, semaglutide (the active ingredient in Wegovy and Ozempic) showed roughly 84% conversion to normal blood sugar in similar populations in the STEP trials. Tirzepatide's dual GIP and GLP-1 receptor agonism appears to give it a metabolic edge, at least in trial settings.
Postpartum weight retention is also a real and under-discussed risk factor for metabolic disease. Research from Endres et al. (2021, Obesity) confirms that retained gestational weight significantly raises the risk of insulin resistance. So the creator's timeline, weight gain after pregnancy leading to pre-diabetes, is clinically coherent.
What did they get wrong (or right)?
The creator gets credit for accuracy here. Saying she is "no longer pre-diabetic" after using a GLP-1/GIP agonist is consistent with what clinical trials show is genuinely possible for a meaningful percentage of users. She is not overclaiming a cure, she is describing a measurable lab result, which is the right way to frame it.
What is missing, and this matters, is any acknowledgment that this result requires sustained medication use and lifestyle changes to maintain. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that participants who stopped tirzepatide regained a substantial portion of lost weight and saw metabolic markers worsen. Pre-diabetes can return. The caption reads like a finish line when, clinically, it is more like a checkpoint.
There is also no mention of side effects. Nausea, vomiting, and gastrointestinal symptoms affect a significant portion of users, particularly during dose escalation. That omission does not make her experience invalid, but it does make the post incomplete as health information.
What should you actually know?
Tirzepatide is not a guaranteed fix for pre-diabetes, but it is one of the more effective pharmacological tools we have right now for metabolic risk reduction. The evidence is real. The results the creator describes are biologically plausible and backed by large randomized trials.
But pre-diabetes reversal with tirzepatide is not a permanent cure. It reflects improved insulin sensitivity and reduced glucose load driven largely by weight loss. If you stop the medication or regain the weight, the metabolic risk can return. Clinicians use the word "remission" deliberately, not "resolution."
If you are considering Zepbound or any GLP-1 class medication, a telehealth provider or physician should be reviewing your metabolic panel, your A1C trajectory, and your full health history before and during treatment. Social media success stories, including this one, are real data points but not clinical guidance. They are one person's outcome in a population where results vary considerably based on starting weight, diet, activity, and individual biology.